

## Generic Prospective Pipeline Summary

### Launch Expected 2012 to 2016 - Sorted by Year and Quarter

*Disclaimer: The information contained herein is compiled from a variety of sources and is provided for informational purposes only. Due to circumstances beyond Caremark's control, information related to prospective drug launch dates is subject to change without notice. This information should not be solely relied upon for decision making purposes. Products containing a Paragraph IV certification inherently involve risks and uncertainties that cannot be predicted or quantified. Actual results may differ from those expressed or implied in this report depending upon a number of factors. These factors include: the difficulty in predicting the timing and outcome of legal proceedings, including patent-related matters such as patent challenge settlements and patent infringement cases; the outcome of litigation arising from challenging the validity or non-infringement of patents covering products; the difficulty of predicting the timing of FDA approvals; court and FDA decisions on exclusivity periods; and the ability of competitors to extend exclusivity periods for their products.*

Trade Name	Therapeutic Class	Manufacturer	Potential Launch	US Brand Sales (\$M)
Zomig ZMT	Serotonin Agonists	Astra Zeneca	Launched 5-14-2013	\$40
Atacand Tabs	Angiotensin II Receptor Antagonists	AstraZeneca	Launched 5-21-2013	\$118
Rilutek	ALS Agents	Sanofi Aventis	Launched 6-18-2013	\$56
Metrogel 1%	Rosacea Agents	Galderma	Launched 7-2-2013	\$96
Trilipix DR Caps	Fibric Acid Derivatives	Abbott (AbbVie)	Launched 7-19-2013	\$552
Soriatane Caps	Antipsoriatics	Stiefel	Launched 7-23-2013	\$133
Prandin Tabs	Meglitinide Analogues	Novo Nordisk	Launched 7-24-2013	\$198
Patanase	Nasal Antiallergy	Alcon	2013-Q2*	\$101
Advicor	HMG CoA Reductase Inhibitors	Abbott	2013-Q3 (Settlement)	\$45
Bromday	Ophthalmics - Misc.	Ista	2013-Q3*	\$107
Lidoderm	Local Anesthetics - Topical	Endo	2013-Q3 (Settlement)	\$1,316
Niaspan	Nicotinic Acid Derivatives	Abbott	2013-Q3 (Settlement)	\$1,073
Temodar	Alkylating Agents	Schering	2013-Q3 (Settlement)	\$392
Aciphex	Proton Pump Inhibitors	Eisai	2013-Q4*	\$843
Cymbalta	Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)	Eli Lilly	2013-Q4*	\$4,094
Exalgo	Opioid Agonists	Mallinckrodt	2013-Q4 (Settlement)	\$106
Locoid Lipocream	Corticosteroids - Topical	Triax Pharma	2013-Q4 (Settlement)	\$35
Vanos	Corticosteroids - Topical	Medicus	2013-Q4*	\$67
Vivelle-Dot	Estrogens	Noven	2013-Q4*	\$263
<b>2014</b>				
Loestrin 24 FE	Combination Contraceptives - Oral	Warner Chilcott	2014-Q1 (Settlement)	\$544
Rapamune Tabs	Immunosuppressive Agents	Pfizer	2014-Q1*	\$186
Renvela Tabs	Phosphate Binder Agents	Genzyme	2014-Q1 (settlement)	\$649
Actonel	Calcium Regulators - Misc.	Warner Chilcott	2014-Q2*	\$250
Copaxone	Multiple Sclerosis Agents	Teva	2014-Q2*	\$3,073
Detrol LA	Urinary Antispasmodics	Pharmacia/Upjohn	2014-Q2*	\$599
Kapvay	Adrenergic Antihypertensives	Shionogi	2014-Q2	\$31
Lunesta	Non-Barbiturate Hypnotics	Sepracor	2014-Q2 (Settlement)	\$778
Nexium	Proton Pump Inhibitors	AstraZeneca	2014-Q2 (Settlement)	\$5,875
Rapamune Soln	Immunosuppressive Agents	Pfizer	2014-Q2*	\$8
Viracept	Antiretrovirals	Viiv	2014-Q2*	\$51
Xeloda	Antimetabolites	Roche	2014-Q2*	\$689
Zemplar Caps	Metabolic Modifiers	Abbott	2014-Q2*	\$108
Avelox	Fluoroquinolones	Bayer	2014-Q3*	\$277
Evista	Hormone Receptor Modulators	Eli Lilly	2014-Q3*	\$711
Micardis Tabs	Angiotensin II Receptor Antagonists	Boehringer Ingelheim	2014-Q3	\$277
Micardis HCT Tabs	Antihypertensive Combinations	Boehringer Ingelheim	2014-Q3	\$221
Renagel	Phosphate Binder Agents	Genzyme	2014-Q3 (settlement)	\$182
Argatroban	Thrombin Inhibitors	GlaxoSmithKline	2014-Q4*	\$96
Intuniv	Alpha-2 Adrenergic Agonist	Shire	2014-Q4 (settlement)	\$440
Nexium IV	Proton Pump Inhibitors	AstraZeneca	2014-Q4*	\$23
Tazorac Gel	Antipsoriatics	Allergan	2014-Q4*	\$31
<b>2015</b>				
Lovaza	Antihyperlipidemics - Misc.	Glaxo	2015-Q1 (settlement)	\$994
Lumigan	Prostaglandins - Ophthalmic	Allergan	2015-Q1*	\$421
Namenda	Antidementia Agents	Forest	2015-Q1 (settlement)	\$1,593
Protopic	Immunosuppressive Agents - Topical	Astellas	2015-Q1*	\$108
Teveten HCT	Antihypertensive Combinations	Abbott	2015-Q1*	\$3
Welchol Tabs	Bile Acid Sequestrants	Daiichi Sankyo	2015-Q1 (settlement)	\$353
Abilify ODT	Quinolinone Derivatives	Otsuka	2015-Q2*	\$17
Abilify Tabs	Quinolinone Derivatives	Otsuka	2015-Q2*	\$5,376
Cipro Susp	Fluoroquinolones	Schering	2015-Q2*	\$8
Oxytrol	Urinary Antispasmodics	Watson	2015-Q2 (settlement)	\$25
Relenza	Influenza Agents	Glaxo	2015-Q2*	\$10
Tobi	Aminoglycosides	Novartis	2015-Q2*	\$297
Travatan Z	Prostaglandins - Ophthalmic	Alcon	2015-Q2*	\$457
Welchol Susp	Bile Acid Sequestrants	Daiichi Sankyo	2015-Q2 (settlement)	\$78
Zyvox Tabs	Oxazolidinones	Pfizer	2015-Q2*	\$706
Zyvox Susp	Oxazolidinones	Pfizer	2015-Q2*	\$15
Zyvox Injection	Oxazolidinones	Pfizer	2015-Q2*	\$1
Aggrenox	Platelet Aggregation Inhibitors	Boehringer Ingelheim	2015-Q3 (settlement)	\$476
Androgel 1%	Androgens	Solvay	2015-Q3 (settlement)	\$878
Baraclude	Hepatitis Agents	BMS	2015-Q3*	\$230
Gleevec	Antineoplastic Enzyme Inhibitors	Novartis	2015-Q3*	\$1,797
Aloxi	5-HT3 Receptor Antagonists	Eisai	2015-Q4*	\$478
Axert	Serotonin Agonists	Ortho	2015-Q4*	\$38
Celebrex	Nonsteroidal Anti-inflammatory Agents (NSAIDs)	Pfizer	2015-Q4*	\$1,775
Doribax	Carbapenems	Janssen	2015-Q4	\$60
Ortho Tri-Cyclen Lo	Combination Contraceptives - Oral	Ortho	2015-Q4 (settlement)	\$426
Patanol	Ophthalmics - Misc.	Alcon	2015-Q4*	\$217
<b>2016</b>				
Cenestin	Estrogens	Duramed/Barr	2016-Q1*	\$24
Coreg CR	Alpha-Beta Blockers	GlaxoSmithKline	2016-Q2*	\$265
Crestor	HMG CoA Reductase Inhibitors	AstraZeneca	2016-Q2 (settlement)	\$4,992
Enablex	Urinary Antispasmodics	Warner Chilcott	2016-Q2 (settlement)	\$258
Frova	Selective Serotonin Agonists 5-HT(1)	Endo	2016-Q2*	\$72
Jalyn	Benign Prostatic Hypertrophy Agent	GlaxoSmithKline	2016-Q2*	\$93
Nuvigil	CNS Stimulant	Cephalon	2016-Q2 (settlement)	\$409
Ortho Evra Patch	Combination Contraceptives - Transderm	Janssen	2016-Q2*	\$72
Azor	Angiotensin II Receptor Antag & Ca Channel Blocker	Daiichi Sankyo	2016-Q4*	\$259

## Generic Prospective Pipeline Summary

### Launch Expected 2012 to 2016 - Sorted by Year and Quarter

*Disclaimer: The information contained herein is compiled from a variety of sources and is provided for informational purposes only. Due to circumstances beyond Caremark's control, information related to prospective drug launch dates is subject to change without notice. This information should not be solely relied upon for decision making purposes. Products containing a Paragraph IV certification inherently involve risks and uncertainties that cannot be predicted or quantified. Actual results may differ from those expressed or implied in this report depending upon a number of factors. These factors include: the difficulty in predicting the timing and outcome of legal proceedings, including patent-related matters such as patent challenge settlements and patent infringement cases; the outcome of litigation arising from challenging the validity or non-infringement of patents covering products; the difficulty of predicting the timing of FDA approvals; court and FDA decisions on exclusivity periods; and the ability of competitors to extend exclusivity periods for their products.*

Trade Name	Therapeutic Class	Manufacturer	Potential Launch	US Brand Sales (\$M)
Benicar	Angiotensin II Receptor Antagonists	Daiichi Sankyo	2016-Q4*	\$771
Benicar HCT	Angiotensin II Receptor Antagonists	Daichi Sankyo	2016-Q4*	\$656
Eпивir HBV Tabs	Antiretrovirals - RTI-Nucleoside Analogues-Pyrimidines	GlaxoSmithKline	2016-Q4*	\$21
Seroquel XR	Dibenzothiazepines	AstraZeneca	2016-Q4 (settlement)	\$1,156
Zetia	Intestinal Cholesterol Absorption Inhibitors	Merck	2016-Q4 (settlement)	\$1,461

*Note: (1) \* Represents launch date including PED extension; (2) Annual brand sales are last twelve months (LTM); (3) Potential first to file ANDAs may entitle 6-months of marketing exclusivity to The content of this report may contain certain forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties relate to, among other things, regulatory, litigation matters, legislative developments, administrative rulings, and supplier risk tolerance. All forward-looking information included on this report speaks only as of the date of the report.*